Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ incorporation or organization) Delaware 33-1051425 (State or other jurisdiction of (I.R.S. Employer Identification No.) (A ...

Neuronetics Inc (NASDAQ:STIM) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO Steve Furlong - SVP, CFO & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Marie Thibault - BTIG David Turkaly - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics' Reports Second Quarter 2022 Financial an ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM August 2022 Disclaimers neurostar.com This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain stat ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM May 2022 Disclaimers n e u r o s t a r . c o m This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Cer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation ...

Neuronetics, Inc. (NASDAQ:STIM) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Mark Klausner – Investor Relations Keith Sullivan – President and Chief Executive Officer Steve Furlong – Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder – Piper Sandler Bill Plovanic – Canaccord Marie Thibault – BTIG Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2022 Financial and Operating Results Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-38546 NEURONETICS, INC. (Exact name of registrant as specified in its charter) incorporation or or ...

Neuronetics, Inc. (NASDAQ:STIM) Q4 2021 Earnings Conference Call March 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Partners Keith Sullivan - President and CEO Steve Furlong - CFO Conference Call Participants Adam Maeder - Piper Sandler Bill Plovanic - Canaccord Genuity Marie Thibault - BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics' Fourth Quarter 2021 Financial and Operating Results Conference Call. At this time, all participants are in a listen-o ...

TAP INTO A NEW POSSIBILITY for depression COMPANY PRESENTATION NASDAQ: STIM March 2022 Disclaimers neurostar.com This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data. Certain state ...